Apogee Therapeutics, Inc.
APGE
$41.96
$0.781.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.67% | -37.13% | -44.96% | -5.37% | -1.13% |
| Total Depreciation and Amortization | 172.37% | 58.33% | 33.33% | 24.14% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.38% | 97.87% | -7.39% | 68.66% | 422.00% |
| Change in Net Operating Assets | 50.49% | -259.89% | 141.57% | 217.44% | -152.06% |
| Cash from Operations | 28.41% | -59.24% | -45.13% | 7.38% | -6.33% |
| Capital Expenditure | -431,800.00% | 100.13% | -1,372.55% | 85.47% | -110.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.69% | 131.84% | 2.04% | -189.26% | -30.02% |
| Cash from Investing | -72.00% | 131.68% | 1.57% | -187.40% | -30.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.60% | -- | -- | -92.70% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -- | -- |
| Cash from Financing | -98.60% | 11,481.20% | 355.33% | -100.03% | 211,611.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -251.56% | 112.21% | -5.82% | -148.53% | 627.05% |